Perceptive Advisors LLC Boosts Holdings in SAB Biotherapeutics, Inc. $SABS

Perceptive Advisors LLC lifted its holdings in SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 700.8% in the first quarter, HoldingsChannel reports. The fund owned 6,431,743 shares of the company’s stock after buying an additional 5,628,533 shares during the period. Perceptive Advisors LLC owned approximately 0.08% of SAB Biotherapeutics worth $24,634,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in SABS. PNC Financial Services Group Inc. bought a new position in shares of SAB Biotherapeutics during the 1st quarter valued at $29,000. State of Wyoming bought a new stake in SAB Biotherapeutics in the fourth quarter worth $34,000. ADAR1 Capital Management LLC boosted its position in SAB Biotherapeutics by 75.6% during the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares during the period. State Street Corp purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $49,000. Finally, Fifth Lane Capital LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at about $56,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Up 0.3%

NASDAQ SABS opened at $3.57 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The stock has a market capitalization of $272.96 million, a PE ratio of -1.69 and a beta of 0.52. SAB Biotherapeutics, Inc. has a 1 year low of $1.85 and a 1 year high of $5.15. The business’s 50-day moving average is $3.67 and its 200 day moving average is $3.83.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SABS has been the topic of several analyst reports. Rodman & Renshaw reiterated a “buy” rating and issued a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Chardan Capital increased their target price on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Citigroup started coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target on the stock. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.